Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 123,102 shares of Jasper Therapeutics, Inc. voting common stock, representing 9.99% of the class as of September 30, 2026.
Key Highlights
- Beneficial ownership: Armistice Capital, LLC and Steven Boyd each report beneficial ownership of 123,102 shares of Jasper Therapeutics voting common stock.
- Percent of class: The 123,102 shares represent 9.99% of the outstanding class, according to the filing.
- No sole voting or dispositive power: Both reporting persons disclose 0 shares with sole voting power and 0 shares with sole dispositive power; all 123,102 shares are held with shared voting and shared dispositive power.
- Direct holder: The filing identifies Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, as the direct holder of the shares.
- Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.
- Ordinary course certification: The reporting persons certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
Armistice Capital and Steven Boyd Disclose Joint 9.99% Position in Jasper Therapeutics
According to the Schedule 13G filed November 16, 2026, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., which the filing identifies as the direct holder of the reported shares. Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities held by the Master Fund and, as a result, may be deemed to beneficially own those securities. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the same 123,102 shares.
The filing notes that the Master Fund "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." The Master Fund, described as a Cayman Islands exempted company and investment advisory client of Armistice Capital, is identified as having "the right to receive dividends from, or the proceeds from the sale of, the reported securities."
The securities are described as voting common stock of Jasper Therapeutics, Inc. (NASDAQ:JSPR), par value $0.0001 per share, with CUSIP number 471871301. Armistice Capital is organized in Delaware, and Steven Boyd is a United States citizen. Both reporting persons are filing jointly pursuant to Rule 13d-1(k), and both signed the statement on November 16, 2026.
What Was Disclosed
Armistice Capital, LLC and Steven Boyd jointly filed a Schedule 13G disclosing beneficial ownership of 123,102 shares, or 9.99%, of Jasper Therapeutics voting common stock as of September 30, 2026, held through Armistice Capital Master Fund Ltd.



Please wait processing your request...